Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop.
about
HIV-1 superinfection in women broadens and strengthens the neutralizing antibody responsePolyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individualsA Blueprint for HIV Vaccine DiscoveryDevelopment of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infectionVirological features associated with the development of broadly neutralizing antibodies to HIV-1Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9Co-evolution of a broadly neutralizing HIV-1 antibody and founder virusDevelopmental pathway for potent V1V2-directed HIV-neutralizing antibodiesBroad and potent neutralization of HIV-1 by a gp41-specific human antibodyFunctional Implications of the Binding Mode of a Human Conformation-Dependent V2 Monoclonal Antibody against HIVDelineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralizationSomatic Hypermutation-Induced Changes in the Structure and Dynamics of HIV-1 Broadly Neutralizing AntibodiesBroadly Neutralizing Antibodies for HIV EradicationAllosteric modulation of the HIV-1 gp120-gp41 association site by adjacent gp120 variable region 1 (V1) N-glycans linked to neutralization sensitivityAn efficiently cleaved HIV-1 clade C Env selectively binds to neutralizing antibodiesHuman antibodies that neutralize HIV-1: identification, structures, and B cell ontogeniesMonoclonal antibodies to the V2 domain of MN-rgp120: fine mapping of epitopes and inhibition of α4β7 bindingBroadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune SystemCooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies.Sequence-conserved and antibody-accessible sites in the V1V2 domain of HIV-1 gp120 envelope protein.Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodiesIncreased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infectionThe Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation.Sequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodies.Unique C2V3 sequence in HIV-1 envelope obtained from broadly neutralizing plasma of a slow progressing patient conferred enhanced virus neutralization.Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models.A novel strategy for efficient production of anti-V3 human scFvs against HIV-1 clade C.Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library.Elicitation of both anti HIV-1 Env humoral and cellular immunities by replicating vaccinia prime Sendai virus boost regimen and boosting by CD40LmN332-Directed broadly neutralizing antibodies use diverse modes of HIV-1 recognition: inferences from heavy-light chain complementation of function.A twin-cysteine motif in the V2 region of gp120 is associated with SIV envelope trimer stabilizationViral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypesThe neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infectionVirological and immunological factors associated with HIV-1 differential disease progression in HLA-B 58:01-positive individualsEstimated secondary structure propensities within V1/V2 region of HIV gp120 are an important global antibody neutralization sensitivity determinant.Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody.Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors.Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency
P2860
Q21090490-50826243-D472-4A1D-9162-966D0C3F061EQ24635002-D051F7AF-C1F3-42FD-9F75-40C1BC6CC2F7Q26829865-33D2F08F-D734-4F17-A796-3EEA7D0E98DDQ27022652-FC592451-83E6-48F5-B2C8-42BAEAAFF912Q27025177-9800992C-20B3-414E-B5A6-65A49BC7C87CQ27644478-ECFCCBE3-4138-4BE7-AF62-11FADFE26047Q27644501-4AB63F03-4E49-43FA-88A2-1877C51A9A5BQ27644515-C1CADC1E-C350-4743-92F1-FD6F23E6E8A5Q27675131-730A9368-82FB-4338-A1DC-722D57A07A5FQ27681527-056E8A64-5A28-4B14-B90C-E1C36743ABC4Q27684578-91F3A380-0796-40CB-AEE8-13D59B480F30Q27723297-D4D469AB-D1AE-4000-85CB-329FAF508832Q28073939-207702F1-3BCF-4197-A986-78D34C29E1ACQ28485983-659A4E7E-626D-4B51-99F6-BBF19DEA8AF3Q28545185-B6EC4E84-63BA-4094-83AA-8C203B317C7FQ28602877-03668F34-4942-4369-B330-BEAEAE7AC323Q28728517-8D5B1913-7473-4833-BB85-9E31531C2D89Q33592852-1B9E5A13-BFBE-417D-9360-2A05D557BFB0Q34114798-F5119041-FCA6-46C7-AA0A-0568312547FDQ34116932-750D2043-59C3-4CC3-AA51-6766A241F20AQ34177732-FB8D0B77-B2CA-4336-B29D-07076DE5444CQ34298408-2A471B1B-0A26-4565-9164-56BABFFE47B5Q34300812-6A1B0A95-552F-4719-95C7-A3385C885610Q34303849-8C7DF0C1-B004-4BC6-AAF6-21C92903C952Q34309493-8FCE37C1-0CFB-42FB-9415-9AB8514CE97CQ34397758-F26A0A74-007B-42DF-A5DF-4E5D9A3BF34DQ34441935-BC2B8632-2AD0-4FCA-9625-ADDA08F83E4DQ34455457-43180C37-AA6E-4107-A78E-0FF5369C505BQ34478387-3FC896B6-D36F-49F9-A186-117F8AF3676BQ34488183-8C9CA490-11C0-4EBD-94F3-620141D9021FQ34511092-AC85DA4F-1642-4F6E-A9B4-BCB0827E4AF1Q34594978-42665EE2-F94B-476B-8C96-662E6A384F18Q34919985-45BC5117-8627-4F9E-9004-6BD5D33D8A40Q35034268-D4202827-4216-4401-92BC-16ACA8931177Q35076717-134BAA72-81A0-4305-9EA8-42AC1FF74D03Q35077768-71ADB819-EF83-4C14-9AEA-BBB058691B9EQ35140508-227EF2AB-7FB6-47B9-B9E0-3CBDE8DBFEC1Q35168642-50E3200A-6459-4194-9FFD-8A0166C34E91Q35382871-CDB987CC-4CC6-4165-9CC3-1A70C5053E00Q35641369-E9795A28-5B89-43CD-AE66-00AC7DF25AA5
P2860
Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Potent and broad neutralizatio ...... uding residues in the V2 loop.
@ast
Potent and broad neutralizatio ...... uding residues in the V2 loop.
@en
Potent and broad neutralizatio ...... uding residues in the V2 loop.
@nl
type
label
Potent and broad neutralizatio ...... uding residues in the V2 loop.
@ast
Potent and broad neutralizatio ...... uding residues in the V2 loop.
@en
Potent and broad neutralizatio ...... uding residues in the V2 loop.
@nl
prefLabel
Potent and broad neutralizatio ...... uding residues in the V2 loop.
@ast
Potent and broad neutralizatio ...... uding residues in the V2 loop.
@en
Potent and broad neutralizatio ...... uding residues in the V2 loop.
@nl
P2093
P2860
P50
P356
P1433
P1476
Potent and broad neutralizatio ...... uding residues in the V2 loop.
@en
P2093
Abraham Pinter
CAPRISA 002 Study
Daniel Sheward
Maphuti Madiga
Molati Nonyane
Nancy Tumba
Nthabeleng Ranchobe
Tandile Hermanus
William J Honnen
P2860
P304
P356
10.1128/JVI.02658-10
P407
P50
P577
2011-01-26T00:00:00Z